Neuropathology of Common Dementias
The neuropathologic examination remains the gold standard for diagnosing neurodegenerative dementias. Over the past two decades, standardized scoring systems — including NIA-AA ABC scoring for Alzheimer disease (AD), Braak staging for tau and Lewy body pathology, and harmonized FTLD-TDP classification — have brought consistency to postmortem diagnosis. Critically, autopsy studies reveal that mixed pathology is the rule rather than the exception in elderly individuals, with the majority of dementia cases in people older than 80 years harboring two or more coexisting proteinopathies. Understanding the neuropathologic substrate of each dementia syndrome is essential for interpreting biomarkers, appreciating clinicopathologic discordance, and contextualizing emerging disease-modifying therapies.
Bottom Line
- AD neuropathology: Defined by extracellular Aβ plaques (neuritic and diffuse) and intraneuronal neurofibrillary tangles (NFTs) of hyperphosphorylated tau; graded using the NIA-AA ABC scoring system integrating Thal amyloid phases (A), Braak NFT stages (B), and CERAD neuritic plaque scores (C)
- LBD neuropathology: Characterized by α-synuclein–positive Lewy bodies and Lewy neurites; classified as olfactory-only, amygdala-predominant, brainstem-predominant, limbic, or neocortical; the vast majority of diffuse LBD cases also harbor AD copathology
- FTLD neuropathology: Classified by the predominant proteinopathy — FTLD-tau (Pick bodies, PSP, CBD), FTLD-TDP (types A–E), or FTLD-FUS; each subtype has distinct inclusion morphology, regional distribution, and genetic associations
- VCI neuropathology: Heterogeneous — includes strategic infarcts, lacunar state, small vessel disease with arteriolosclerosis, and white matter rarefaction; cerebral amyloid angiopathy (CAA) bridges vascular and AD pathology
- LATE: TDP-43 proteinopathy in limbic structures (amygdala → hippocampus → middle frontal gyrus) affects >20% of individuals older than 80 years; associated with hippocampal sclerosis in ~70% of cases
- Mixed pathology: Extremely common in elderly dementia; additive and synergistic interactions among Aβ, tau, α-synuclein, TDP-43, and vascular lesions complicate clinicopathologic correlation
Alzheimer Disease Neuropathology
Amyloid-Beta Plaques
Extracellular aggregates of amyloid-beta (Aβ) — derived from sequential enzymatic cleavage of the amyloid precursor protein (APP) — are one of the two defining hallmarks of AD. Aβ plaques are primarily composed of fibrillar Aβ with high Aβ42/Aβ40 ratios and are categorized into two major types:
- Diffuse plaques: Represent an early stage of Aβ deposition; lack a dense amyloid core and are not surrounded by dystrophic neurites; may be found in cognitively normal elderly individuals
- Neuritic plaques: The more mature and pathologically significant form; characterized by a dense core of highly aggregated Aβ surrounded by dystrophic neurites containing phosphorylated tau, activated microglia (disease-associated microglia), and reactive astrocytes
The plaque microenvironment represents dynamic interactions among multiple cell types, between fibrillar and oligomeric amyloid species, and between amyloid and other proteins such as endolysosomal proteins. In advanced stages, amyloid deposition reaches a plateau where both diffuse and neuritic plaques coexist throughout the neocortex.
Neurofibrillary Tangles and Tau Pathology
The second defining hallmark is intraneuronal aggregates of hyperphosphorylated tau. Tau is a microtubule-associated protein encoded by the MAPT gene; alternative splicing produces six isoforms including three-repeat (3R) and four-repeat (4R) forms. In AD, both 3R and 4R isoforms aggregate. The spectrum of tau pathology includes:
- Pretangles: Early accumulations of oligomeric tau in the cytoplasm
- Mature neurofibrillary tangles (NFTs): Dense aggregates of paired helical filaments in the somatodendritic compartment
- Ghost tangles: Extracellular remnants that persist after neuronal death
- Neuropil threads: Tau aggregates in dendrites and, to a lesser extent, axons
- Dystrophic neurites: Tau-positive processes surrounding neuritic plaques
Tau pathology correlates more closely with neurodegeneration, regional atrophy, and cognitive decline than does amyloid burden. Normal tau resides primarily in axons, but pathologic tau mislocalizes to dendrites and the somatodendritic compartment. Oligomeric tau is also present in synapses, where it may contribute to glial-mediated synapse elimination during early AD progression.
Cerebral Amyloid Angiopathy (CAA)
- Aβ deposits frequently accumulate in the walls of small blood vessels and capillaries of the cerebral cortex
- CAA may occur in isolation or in association with AD; it can be hereditary or sporadic
- Severe CAA renders vessels susceptible to intracerebral hemorrhage and is a key substrate for amyloid-related imaging abnormalities (ARIA) during anti-amyloid immunotherapy
- Inflammatory CAA: In some patients, amyloid buildup triggers an autoimmune response — lymphocytic perivascular infiltrate (CAA-related inflammation) or angiodestructive Abeta-related angiitis — causing rapidly progressive dementia
- APOEε4 promotes Aβ deposition in the tunica media of small and medium-sized arteries, driving CAA pathology
Staging and Grading Systems
| Scoring System | What It Measures | Stages/Scores | Key Details |
|---|---|---|---|
| Thal Phases (A score) | Distribution of Aβ plaque deposition | Phases 0–5 | Phase 1: neocortex; Phase 2: hippocampus/limbic; Phase 3: basal ganglia/thalamus; Phase 4: brainstem; Phase 5: cerebellum |
| Braak NFT Stages (B score) | Distribution of neurofibrillary tangles | Stages I–VI | I–II: transentorhinal; III–IV: limbic (hippocampus, entorhinal); V–VI: neocortical (associative → primary cortices) |
| CERAD Score (C score) | Density of neuritic plaques in neocortex | None / Sparse / Moderate / Frequent | Semi-quantitative assessment in standard neocortical sections (frontal, temporal, parietal) |
NIA-AA ABC Scoring
The current consensus diagnostic criteria for AD neuropathologic change integrate all three systems into a single ABC score. Both amyloid and tau pathology are required for a diagnosis of AD neuropathologic change. Cases with amyloid-only pathology represent an early or preclinical stage, while cases with tau-only pathology are classified as primary age-related tauopathy (PART).
| ABC Score | A (Thal Phase) | B (Braak Stage) | C (CERAD) | Level of AD Neuropathologic Change |
|---|---|---|---|---|
| A0, B0–VI, C0–3 | Phase 0 | Any | Any | Not AD |
| A1, B0–II, C0–1 | Phase 1–2 | 0–II | None–Sparse | Low |
| A2, B0–III, C0–2 | Phase 3 | 0–III | None–Moderate | Intermediate |
| A3, B≥III, C≥2 | Phase 4–5 | ≥III | ≥Moderate | High |
Resistance vs Resilience in AD
- Resistance: The ability to avoid accumulating significant AD pathology during aging; these individuals maintain low Aβ and tau burden
- Resilience: The ability to remain cognitively normal despite harboring significant AD pathology at autopsy
- Factors influencing resistance vs resilience include age, genetic background (particularly APOE genotype), cognitive reserve, education, and environmental exposures
- Understanding these phenotypes is critical for interpreting clinicopathologic discordance and evaluating biomarker thresholds
AD Heterogeneity
AD is heterogeneous in both clinical manifestation and pathology. Variants include posterior cortical atrophy (prominent visuospatial deficits with severe occipital involvement), limbic-sparing AD, and limbic-predominant AD, each reflecting distinct patterns of atrophy and neurofibrillary tangle density. In 2021, molecular subtypes of AD were proposed based on transcriptomic profiling, with predominant pathophysiologic mechanisms involving tau, Aβ, neuroinflammation, synaptic function, mitochondrial activity, and myelination.
Lewy Body Disease Neuropathology
Core Pathologic Features
The pathologic hallmark of Lewy body disease (encompassing Parkinson disease and Lewy body dementia) is the Lewy body — an eosinophilic, intraneuronal inclusion within neuronal somas — and Lewy neurites in neuronal processes. Both consist of misfolded α-synuclein protein fibrils. A distinct synucleinopathy is multiple system atrophy (MSA), characterized by α-synuclein–positive glial cytoplasmic inclusions primarily in oligodendrocytes, rather than neurons.
Classification of Lewy Body Pathology
| Stage | Brain Regions Involved | Typical Clinical Correlate |
|---|---|---|
| Olfactory-only | Olfactory bulb | Typically asymptomatic |
| Amygdala-predominant | Amygdala | Typically asymptomatic; frequently found incidentally in AD brains |
| Brainstem-predominant | Dorsal motor nucleus of vagus, substantia nigra | Parkinson disease (motor predominant) |
| Limbic (transitional) | Brainstem + amygdala, cingulate cortex, medial temporal cortex | Parkinson disease with behavioral/cognitive symptoms |
| Neocortical (diffuse) | Brainstem + limbic + frontal, parietal cortex | Dementia with Lewy bodies / Parkinson disease dementia |
In Parkinson disease, the substantia nigra shows characteristic loss of dopaminergic neurons, extracellular neuromelanin deposits, reactive gliosis, and Lewy bodies. In advanced stages, substantia nigra Lewy bodies can become very rare as the neurons that harbored them have been lost. The distinction between Parkinson disease dementia and dementia with Lewy bodies relies entirely on clinical criteria (the "1-year rule"); at autopsy, both show neocortical/diffuse Lewy body disease.
Mixed LBD/AD Pathology
The vast majority of people with diffuse Lewy body disease also present with AD neuropathologic changes — amyloid plaques and neurofibrillary tangles — which are diagnosed and graded using the same NIA-AA criteria. Although synergistic interactions between α-synuclein, Aβ, and tau have been demonstrated experimentally, why AD pathology develops almost inexorably in diffuse LBD brains remains unknown. The neuropathologic basis for the characteristic cognitive fluctuations, visual hallucinations, and sleep disturbances in LBD also remains unclear.
Frontotemporal Lobar Degeneration (FTLD)
FTLD is the umbrella neuropathologic term for the diseases found in patients with clinical frontotemporal dementia (FTD) syndromes. FTLD is primarily classified based on the predominant proteinopathy and genetics.
FTLD-Tau
FTLD-tau is subclassified by the tau isoforms present in inclusions:
| Entity | Tau Isoform | Hallmark Inclusions | Regional Predilection |
|---|---|---|---|
| Pick Disease | 3R | Pick bodies — round, perinuclear inclusions in pyramidal and granular neurons (including dentate gyrus) | Frontal and temporal cortex |
| Progressive Supranuclear Palsy (PSP) | 4R | Tufted astrocytes (most abundant), coiled bodies, globose neuronal tangles (brainstem) | Substantia nigra, brainstem nuclei, cerebellar dentate, subthalamic nucleus, pallidum, hippocampus |
| Corticobasal Degeneration (CBD) | 4R | Astrocytic plaques (hallmark), coiled bodies, threadlike processes in white matter, globose tangles | Primary motor and somatosensory cortices, putamen; heavy white matter involvement |
| Globular Glial Tauopathy | 4R | Distinctive globular oligodendroglial and astrocytic inclusions | Frontotemporal distribution |
| FTD with parkinsonism linked to chr 17 (MAPT) | 3R, 4R, or mixed | Variable neuronal and glial tau inclusions | Variable depending on specific mutation |
FTLD-TDP
FTLD-TDP is characterized by TDP-43/ubiquitin–positive inclusions along with loss of normal nuclear TDP-43 expression. The inclusions include neuronal cytoplasmic inclusions (NCIs), neuronal intranuclear inclusions (NIIs), dystrophic neurites (DNs), and glial cytoplasmic inclusions (GCIs). A harmonized classification system categorizes FTLD-TDP into subtypes based on predominant inclusion type:
| FTLD-TDP Type | Predominant Inclusions | Clinical Association | Genetic Association |
|---|---|---|---|
| Type A | NCIs + short DNs + NIIs | bvFTD, nfvPPA | GRN mutations |
| Type B | Predominantly NCIs across cortical layers | bvFTD, FTD-MND | C9orf72 expansion |
| Type C | Predominantly long DNs | svPPA (semantic dementia) | Usually sporadic |
| Type D | Predominantly NIIs + DNs | Inclusion body myopathy with Paget disease | VCP mutations |
| Type E | Granulofilamentous NCIs + fine grains | Rapidly progressive bvFTD | Usually sporadic |
C9orf72 hexanucleotide repeat expansion is the most common genetic cause of both familial and sporadic FTD and ALS, accounting for 25% of familial FTD and 6% of apparently sporadic cases.
FTLD-FUS and Rare Subtypes
FTLD-FUS features inclusions of the fused in sarcoma (FUS) protein and is rare, typically affecting younger patients. FTLD-UPS shows ubiquitin inclusions (associated with CHMP2B variants), and FTLD-not-otherwise-specified lacks distinctive inclusions of tau, TDP-43, FUS, or ubiquitin.
Vascular Cognitive Impairment (VCI) Neuropathology
Vascular contributions to cognitive impairment encompass a heterogeneous group of pathologies. Unlike the proteinopathies, VCI neuropathology reflects damage from ischemia, hemorrhage, and chronic hypoperfusion. Key substrates include:
- Strategic infarcts: Single infarcts in functionally critical locations (e.g., thalamus, angular gyrus, caudate, hippocampus) can produce disproportionate cognitive deficits
- Lacunar infarcts: Small (<15 mm) cavitated infarcts from occlusion of penetrating arterioles; accumulation in basal ganglia and white matter produces the "lacunar state"
- Microinfarcts: Visible only microscopically; increasingly recognized as an important contributor to cognitive decline, particularly when cortical and numerous
- Small vessel disease (arteriolosclerosis): Hyaline thickening and fibrosis of arteriolar walls; leads to chronic hypoperfusion and white matter injury
- White matter rarefaction (leukoaraiosis): Pallor, myelin loss, and gliosis in periventricular and deep white matter; disrupts cortical-subcortical connectivity
- Cerebral amyloid angiopathy: Aβ deposition in vessel walls causing lobar hemorrhages, microbleeds, and cortical superficial siderosis; bridges vascular and AD pathology
Vascular Pathology as a Copathology
- Vascular lesions frequently coexist with neurodegenerative proteinopathies and have additive effects on cognitive decline
- Even small vascular lesion burdens can unmask or accelerate clinical dementia in the presence of subclinical AD pathology
- The AT(N) biomarker framework now includes a "V" category (vascular injury) — assessed by MRI (infarcts, white matter hyperintensities, enlarged perivascular spaces) and at autopsy
- "Pure" vascular dementia without any neurodegenerative copathology is relatively uncommon in the elderly
LATE Neuropathology
Limbic-predominant age-related TDP-43 encephalopathy (LATE) is estimated to affect more than 20% of individuals older than 80 years. It is a recently recognized entity that contributes significantly to dementia in the oldest old.
LATE Staging
- Stage 1: TDP-43 proteinopathy confined to the amygdala
- Stage 2: Extension to the hippocampus
- Stage 3: Involvement of the middle frontal gyrus
The neuropathologic hallmark is loss of normal nuclear TDP-43 immunoreactivity with inclusions of phosphorylated TDP-43 in neuronal cytoplasm, nucleus, or both. The TDP-43 staining pattern resembles FTLD-TDP type A but does not fit precisely into established FTLD-TDP subtypes. LATE is associated with hippocampal sclerosis — defined pathologically as near-total neuronal loss and gliosis in the hippocampal CA1 region and subiculum — in more than 70% of cases. Genetic risk factors include variants in GRN, TMEM106B, ABCC9, KCNMB2, and APOEε4.
Chronic Traumatic Encephalopathy (CTE)
CTE is a progressive tauopathy associated with repetitive head impacts, most studied in contact sport athletes and military veterans. The pathognomonic lesion is the accumulation of hyperphosphorylated tau in neurons, astrocytes, and cell processes around small blood vessels at the depths of cortical sulci (perivascular tau). This distribution pattern is unique to CTE and distinguishes it from other tauopathies.
- CTE tau pathology consists of both 3R and 4R tau isoforms, similar to AD
- Unlike AD, the earliest tau deposits in CTE occur at the depths of sulci rather than in the transentorhinal cortex
- Advanced CTE may also show TDP-43 pathology, Aβ plaques, and Lewy body copathology
- Currently, CTE can only be definitively diagnosed at autopsy; no validated in vivo biomarkers exist
- A 2023 consensus update proposed four neuropathologic stages of CTE severity based on the extent and distribution of perivascular tau
Prion Disease Neuropathology
Prion diseases are unique among neurodegenerative disorders due to the self-propagating and transmissible nature of the abnormal prion protein (PrPSc). Forms include sporadic Creutzfeldt-Jakob disease (sCJD), genetic prion diseases (familial CJD, Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia), and acquired forms (variant CJD, iatrogenic CJD).
Core Pathologic Features
- Spongiform change (spongiosis): Microvacuolization resulting from neuropil damage in the gray matter; the hallmark finding of prion disease
- PrPSc deposits: Abnormal prion protein accumulation in various patterns (diffuse/synaptic, perivacuolar, plaque-like); can form amyloid plaques distinct from Aβ plaques
- Neuronal loss and gliosis: Progressive and accompanied by reactive astrocytosis
- Absence of significant inflammatory infiltrate: Unlike most other CNS diseases, prion diseases characteristically lack a lymphocytic response
| Prion Disease | Primary Region Affected | Distinguishing Pathologic Feature |
|---|---|---|
| Sporadic CJD | Neocortex (variable distribution) | Spongiform change with synaptic PrP deposits; cortical ribboning on MRI |
| Familial CJD | Neocortex (variable) | Overlapping with sCJD; specific PRNP variants associated with distinct phenotypes |
| Gerstmann-Sträussler-Scheinker | Cerebellum | Multicentric PrP amyloid plaques in cerebellar cortex |
| Fatal familial insomnia | Thalamus | Selective thalamic neuronal loss and gliosis; minimal spongiform change |
| Variant CJD | Cerebral cortex and cerebellum | "Florid plaques" — PrP amyloid plaques surrounded by spongiform vacuoles |
Primary Age-Related Tauopathy (PART) and ARTAG
Two additional age-related tau pathologies merit recognition:
- PART: Characterized by AD-type tau pathology (3R + 4R isoforms) without or with only sparse Aβ plaques; primarily involves the medial temporal lobe, basal forebrain, brainstem, and olfactory areas; rarely spreads to neocortex; may represent a distinct entity or the earliest stage of the AD spectrum
- Age-related tau astrogliopathy (ARTAG): Features 4R tau-immunopositive inclusions in astrocytes (thorn-shaped and granular/fuzzy astrocytes) located in subpial, subependymal, and perivascular areas; morphologically distinct from tufted astrocytes of PSP or astrocytic plaques of CBD; clinical significance remains uncertain
Mixed Pathology and Clinicopathologic Correlation
Comprehensive neuropathologic studies consistently demonstrate that mixed pathology is extremely common in elderly individuals with dementia. Community-based autopsy studies show that most dementia cases in persons older than 80 years harbor two or more coexisting proteinopathies.
| Copathology Combination | Estimated Prevalence in Dementia | Clinical Impact |
|---|---|---|
| AD + LBD | ~50–60% of LBD cases | Worse memory performance; faster progression; higher NFT burden than pure LBD |
| AD + vascular pathology | ~30–40% of AD cases | Lower threshold of AD pathology needed to produce dementia; additive cognitive effects |
| AD + LATE | ~20–50% in oldest old | Accelerated hippocampal atrophy and memory decline beyond what AD pathology alone predicts |
| AD + LBD + vascular | Common in individuals >85 years | Cumulative contributions from multiple proteinopathies; complex clinical phenotype |
| LBD + LATE | Under investigation | Emerging evidence of synergistic effects on limbic neurodegeneration |
Challenges in Clinicopathologic Correlation
- No single proteinopathy explains all clinical features in most elderly dementia patients — the additive and synergistic effects of mixed pathology complicate prediction from clinical phenotype alone
- Approximately 10–30% of clinically diagnosed AD cases have a different primary pathology at autopsy (LBD, FTLD, VCI, or LATE)
- Biomarker-negative individuals with clinical dementia may harbor pathologies not yet detectable in vivo (e.g., LATE, ARTAG, hippocampal sclerosis)
- People without dementia who harbor significant AD pathology at autopsy ("resilient" individuals) challenge the assumption that pathology inevitably produces clinical disease
- Comprehensive postmortem examination describing both primary pathology and copathologies is essential for correlating biomarkers with underlying neuropathology and evaluating therapeutic effects
Summary of Key Neuropathologic Features
| Disease | Defining Protein | Hallmark Inclusions | Key Staging System |
|---|---|---|---|
| Alzheimer disease | Aβ + hyperphosphorylated tau (3R + 4R) | Neuritic plaques, NFTs, neuropil threads, dystrophic neurites | NIA-AA ABC score (Thal / Braak / CERAD) |
| Lewy body disease | α-synuclein | Lewy bodies (neuronal), Lewy neurites | Brainstem → limbic → neocortical staging |
| FTLD-tau | Tau (3R or 4R depending on subtype) | Pick bodies, tufted astrocytes, astrocytic plaques, globose tangles | Subtype-specific classification |
| FTLD-TDP | TDP-43 | NCIs, NIIs, dystrophic neurites, GCIs | Harmonized types A–E |
| VCI | N/A (ischemic/hemorrhagic injury) | Infarcts, microinfarcts, white matter rarefaction, arteriolosclerosis | No single consensus staging system |
| LATE | TDP-43 | Limbic TDP-43 inclusions ± hippocampal sclerosis | Stages 1–3 (amygdala → hippocampus → frontal) |
| CTE | Hyperphosphorylated tau (3R + 4R) | Perivascular tau at depths of cortical sulci | 4-stage consensus system |
| Prion disease | PrPSc | Spongiform change, PrP deposits/plaques | Subtype-specific regional patterns |
References
- Scholz SW, Cobos I. Genetics and neuropathology of neurodegenerative dementias. Continuum (Minneap Minn). 2024;30(6, Dementia):1801-1822.
- Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1-13.
- Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11.
- Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
- Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800.
- Attems J, Toledo JB, Walker L, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141(2):159-172.
- McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
- Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration (FTLD-tau). J Mol Neurosci. 2011;45(3):384-389.
- Mackenzie IRA, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111-113.
- Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503-1527.
- Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-766.
- Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131(1):87-102.
- Robinson JL, Richardson H, Xie SX, et al. The development and convergence of co-pathologies in Alzheimer's disease. Brain. 2021;144(3):953-962.
- Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90(15):695-703.
- Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143-5169.